2-Arachidonoylglycerol: A novel inhibitor of androgen-independent prostate cancer cell invasion

Kasem Nithipatikom, Michael P. Endsley, Marilyn A. Isbell, J R Falck, Yoshiki Iwamoto, Cecilia J. Hillard, William B. Campbell

Research output: Contribution to journalArticlepeer-review

119 Scopus citations


Endocannabinoids have been implicated in cancer. Increasing endogenous 2-arachidonoylglycerol (2-AG) by blocking its metabolism inhibits invasion of androgen-independent prostate cancer (PC-3 and DU-145) cells. Noladin ether (a stable 2-AG analog) and exogenous CB1 receptor agonists possess similar effects. Conversely, reducing endogenous 2-AG by inhibiting its synthesis or blocking its binding to CB1 receptors with antagonists increases the cell invasion. 2-AG and noladin ether decrease protein kinase A activity in these cells, indicating coupling of the CB1 receptor to downstream effectors. The results suggest that cellular 2-AG, acting through the CB1 receptor, is an endogenous inhibitor of invasive prostate cancer cells.

Original languageEnglish (US)
Pages (from-to)8826-8830
Number of pages5
JournalCancer research
Issue number24
StatePublished - Dec 15 2004

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of '2-Arachidonoylglycerol: A novel inhibitor of androgen-independent prostate cancer cell invasion'. Together they form a unique fingerprint.

Cite this